From NYSE: Nabla Bio is using AI and its own dry and wet lab models to discover and develop new antibody and protein based therapeutics. One partner, Takeda, has already come back for more

4 hours ago
1 min read

Co-Founder and CEO Surge Biswas walks us through the platform and describes the type of work that Nabla is doing for partners. Currently, it already has struck deals with Bristol, Astra, and Takeda (twice).

Recent Posts

See All

From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program

Oxford, UK based Oxford BioTherapeutics has steadily been rolling out new partnerships, most recently with Bristol, Roche, and GSK, for its antibody and target discovery work

Oxford, UK based Sitryx has been busy lately with a deal announced with Boehringer Ingelheim, and its lead program targeting PKM2 in the clinic for atopic dermatitis

From NYSE: Nabla Bio is using AI and its own dry and wet lab models to discover and develop new antibody and protein based therapeutics. One partner, Takeda, has already come back for more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight